RGC – Regencell Bioscience Holdings Ltd

RGC — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

1.07

Margin Of Safety %

Put/Call OI Ratio

1.52

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

23.39

Target Price

Analyst Recom

Performance Q

10.26

Upside

-100.6%

Beta

2.27

Ticker: RGC

15 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	RGC	25.44	2.34	0.66	5013
2026-03-10	RGC	24.65	2.22	0.50	4956
2026-03-11	RGC	23.7	2.03	0.04	5270
2026-03-12	RGC	23.9	1.93	1.58	5357
2026-03-13	RGC	24	1.93	1.60	5357
2026-03-17	RGC	22.88	1.81	0.82	5457
2026-03-18	RGC	26.47	1.81	0.42	5434
2026-03-19	RGC	26.97	1.74	0.09	5759
2026-03-20	RGC	27.2	1.71	0.60	5804
2026-03-23	RGC	25.02	1.41	1.87	2655
2026-03-24	RGC	24.3	1.52	1.88	2790
2026-03-25	RGC	24.3041	1.53	0.36	2867
2026-03-26	RGC	25.27	1.52	1.50	2872
2026-03-27	RGC	25.68	1.51	1.18	2880
2026-03-30	RGC	23.39	1.52	0.16	2871
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

15 items 1 of 1

15 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	RGC	25.71	-	-	-
2026-03-10	RGC	24.66	-	-	-
2026-03-11	RGC	23.80	-	-	-
2026-03-12	RGC	24.12	-	-	-
2026-03-13	RGC	23.15	-	-	-
2026-03-17	RGC	22.98	-	-	-
2026-03-18	RGC	26.39	-	-	-
2026-03-19	RGC	26.96	-	-	-
2026-03-20	RGC	27.20	-	-	-
2026-03-23	RGC	25.16	-	-	-
2026-03-24	RGC	24.30	-	-	-
2026-03-25	RGC	24.38	-	-	-
2026-03-26	RGC	25.32	-	-	-
2026-03-27	RGC	26.33	-	-	-
2026-03-30	RGC	23.39	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

15 items 1 of 1

15 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	RGC	0.00	-8.67	1.19
2026-03-10	RGC	0.00	-8.67	1.19
2026-03-11	RGC	0.00	-8.67	1.12
2026-03-12	RGC	0.00	-8.67	1.12
2026-03-13	RGC	0.00	-8.67	1.12
2026-03-17	RGC	0.00	-8.44	1.12
2026-03-18	RGC	0.00	-8.44	1.12
2026-03-19	RGC	0.00	-8.44	1.12
2026-03-20	RGC	0.00	-8.44	1.12
2026-03-23	RGC	0.00	-7.57	1.12
2026-03-24	RGC	0.00	-7.57	1.12
2026-03-25	RGC	0.00	-7.57	1.07
2026-03-26	RGC	0.00	-7.57	1.07
2026-03-27	RGC	0.00	-7.57	1.07
2026-03-30	RGC	0.00	-7.57	1.07
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

15 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-7.57

Beta

2.27

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

97.5

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

2373.35

P/Free Cash Flow

EPS

-0.01

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.18

Return on Equity vs Sector %

-101.2

Return on Equity vs Industry %

-80.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ RGC Healthcare

$23.33

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

14/20

Pullback

15/25

Volume

11/15

Valuation

6/20

TP/AR

2/10

Options

3/10

RSI

43.5

Range 1M

33.6%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

8/25

Growth

11/30

Estimates

0/20

Inst/Vol

3/15

Options

6/10

EPS Yr

EPS NY

52W%

27.3%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

Quality

2/30

Valuation

2/30

Growth

6/25

Stability

6/10

LT Trend

2/5

Quality

Regencell Bioscience Holdings L

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 10

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

RGC

Latest News

—

Caricamento notizie per RGC…

stock quote shares RGC – Regencell Bioscience Holdings Ltd Stock Price stock today

news today RGC – Regencell Bioscience Holdings Ltd stock forecast ,stock prediction 2023 2024 2025

marketwatch RGC – Regencell Bioscience Holdings Ltd yahoo finance google finance

stock history RGC – Regencell Bioscience Holdings Ltd invest stock market

stock prices RGC premarket after hours

ticker RGC fair value insiders trading

TXMD – TherapeuticsMD Inc.

TXMD — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

0.42

Margin Of Safety %

-15

Put/Call OI Ratio

0.03

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

1.98

Target Price

Analyst Recom

Performance Q

14.37

Upside

-80.4%

Beta

0.53

Ticker: TXMD

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-02	TXMD	2.24	0.03	0.00	1172
2026-03-03	TXMD	2.3	0.03	0.00	1172
2026-03-04	TXMD	2.2	0.03	0.00	1172
2026-03-05	TXMD	2.25	0.03	0.00	1171
2026-03-06	TXMD	2.27	0.03	0.00	1171
2026-03-09	TXMD	2.32	0.03	0.00	1183
2026-03-10	TXMD	2.33	0.03	0.00	1186
2026-03-11	TXMD	2.28	0.03	0.00	1186
2026-03-12	TXMD	2.33	0.03	0.00	1186
2026-03-13	TXMD	2.28	0.03	0.00	1186
2026-03-17	TXMD	2.29	0.03	0.01	1254
2026-03-18	TXMD	2.24	0.03	15.00	1382
2026-03-19	TXMD	2.24	0.03	15.00	1382
2026-03-20	TXMD	2.26	0.04	0.00	1398
2026-03-23	TXMD	2.34	0.03	0.00	1083
2026-03-24	TXMD	2.34	0.03	0.50	1095
2026-03-25	TXMD	2.3	0.03	0.50	1095
2026-03-26	TXMD	2.22	0.03	0.00	1098
2026-03-27	TXMD	2.11	0.03	0.00	1103
2026-03-30	TXMD	2.01	0.03	0.00	1105
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	TXMD	2.26	-	-	-
2026-03-03	TXMD	2.30	-	-	-
2026-03-04	TXMD	2.26	-	-	-
2026-03-05	TXMD	2.23	-	-	-
2026-03-06	TXMD	2.26	-	-	-
2026-03-09	TXMD	2.31	-	-	-
2026-03-10	TXMD	2.32	-	-	-
2026-03-11	TXMD	2.30	-	-	-
2026-03-12	TXMD	2.30	-	-	-
2026-03-13	TXMD	2.18	-	-	-
2026-03-17	TXMD	2.26	-	-	-
2026-03-18	TXMD	2.22	-	-	-
2026-03-19	TXMD	2.24	-	-	-
2026-03-20	TXMD	2.25	-	-	-
2026-03-23	TXMD	2.33	-	-	-
2026-03-24	TXMD	2.30	-	-	-
2026-03-25	TXMD	2.30	-	-	-
2026-03-26	TXMD	2.26	-	-	-
2026-03-27	TXMD	2.22	-	-	-
2026-03-30	TXMD	1.98	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	TXMD	4.69	0.79	0.41
2026-03-03	TXMD	4.69	0.79	0.41
2026-03-04	TXMD	4.69	0.79	0.41
2026-03-05	TXMD	4.69	0.79	0.41
2026-03-06	TXMD	4.69	0.79	0.41
2026-03-09	TXMD	4.69	0.79	0.41
2026-03-10	TXMD	4.69	0.79	0.41
2026-03-11	TXMD	4.69	0.79	0.40
2026-03-12	TXMD	4.69	0.79	0.40
2026-03-13	TXMD	4.69	0.79	0.40
2026-03-17	TXMD	4.69	0.79	0.40
2026-03-18	TXMD	4.69	0.79	0.40
2026-03-19	TXMD	4.69	0.79	0.40
2026-03-20	TXMD	4.69	0.79	0.40
2026-03-23	TXMD	4.69	0.79	0.40
2026-03-24	TXMD	4.69	0.79	0.40
2026-03-25	TXMD	4.69	0.79	0.42
2026-03-26	TXMD	4.69	0.79	0.42
2026-03-27	TXMD	4.69	0.79	0.42
2026-03-30	TXMD	4.69	0.79	0.42
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

4.69

Institutional Transactions

0.79

Beta

0.53

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

1.68

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

97.3

Max Drawdown 5-Year %

-99

Target Price

P/E

76.25

Forward P/E

PEG

P/S

8.23

P/B

0.84

P/Free Cash Flow

11.13

EPS

0.03

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

10.8

Relative Volume

0.53

Return on Equity vs Sector %

-26.3

Return on Equity vs Industry %

-6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ TXMD Healthcare

$1.99

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

14/20

Pullback

17/25

Volume

11/15

Valuation

12/20

TP/AR

0/10

Options

8/10

RSI

31.8

Range 1M

2.3%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

7/25

Growth

7/30

Estimates

1/20

Inst/Vol

6/15

Options

6/10

EPS Yr

EPS NY

52W%

53.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +51.2% upside

Quality

6/30

Valuation

15/30

Growth

5/25

Stability

7/10

LT Trend

1/5

Upside

+51.2%

Quality

MoS

-15%

TherapeuticsMD, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 1

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

TXMD

Latest News

—

Caricamento notizie per TXMD…

stock quote shares TXMD – TherapeuticsMD Inc. Stock Price stock today

news today TXMD – TherapeuticsMD Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch TXMD – TherapeuticsMD Inc. yahoo finance google finance

stock history TXMD – TherapeuticsMD Inc. invest stock market

stock prices TXMD premarket after hours

ticker TXMD fair value insiders trading

EVO – Evotec SE

EVO — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

0.12

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

-0.01

EPS This/Next Y

0.31

Price

2.38

Target Price

3.8

Analyst Recom

2.09

Performance Q

-24.12

Upside

-566.1%

Beta

1.93

Ticker: EVO

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-02	EVO	3.3	N/A	N/A	0
2026-03-03	EVO	3.08	N/A	N/A	0
2026-03-04	EVO	3.28	N/A	N/A	0
2026-03-05	EVO	3.12	N/A	N/A	0
2026-03-06	EVO	3.08	N/A	N/A	0
2026-03-09	EVO	3.03	N/A	N/A	0
2026-03-10	EVO	2.66	N/A	N/A	0
2026-03-11	EVO	2.5	N/A	N/A	0
2026-03-12	EVO	2.43	N/A	N/A	0
2026-03-13	EVO	2.41	N/A	N/A	0
2026-03-17	EVO	2.47	N/A	N/A	0
2026-03-18	EVO	2.45	N/A	N/A	0
2026-03-19	EVO	2.45	N/A	N/A	0
2026-03-20	EVO	2.41	N/A	N/A	0
2026-03-23	EVO	2.38	N/A	N/A	0
2026-03-24	EVO	2.36	N/A	N/A	0
2026-03-25	EVO	2.52	N/A	N/A	0
2026-03-26	EVO	2.47	N/A	N/A	0
2026-03-27	EVO	2.42	N/A	N/A	0
2026-03-30	EVO	2.38	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	EVO	3.29	-	108.8	-0.66
2026-03-03	EVO	3.07	-	109.9	-0.66
2026-03-04	EVO	3.28	-	105.4	-0.66
2026-03-05	EVO	3.12	-	109.2	-0.66
2026-03-06	EVO	3.08	-	108.1	-0.66
2026-03-09	EVO	3.03	-	110.9	-0.66
2026-03-10	EVO	2.67	-	114.3	-0.66
2026-03-11	EVO	2.50	-	113.0	-0.66
2026-03-12	EVO	2.44	-	111.3	-0.66
2026-03-13	EVO	2.32	-	112.4	-0.66
2026-03-17	EVO	2.46	-	106.2	-0.66
2026-03-18	EVO	2.45	-	106.5	-0.66
2026-03-19	EVO	2.46	-	106.3	-0.66
2026-03-20	EVO	2.43	-	106.8	-0.66
2026-03-23	EVO	2.38	-	107.5	-0.66
2026-03-24	EVO	2.35	-	108.1	-0.66
2026-03-25	EVO	2.52	-	105.4	-0.66
2026-03-26	EVO	2.46	-	106.2	-0.66
2026-03-27	EVO	2.42	-	107.0	-0.66
2026-03-30	EVO	2.38	-	106.9	-0.66
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	EVO	0.00	-1.88	0.08
2026-03-03	EVO	0.00	-1.88	0.08
2026-03-04	EVO	0.00	-1.88	0.08
2026-03-05	EVO	0.00	-1.88	0.08
2026-03-06	EVO	0.00	-1.88	0.08
2026-03-09	EVO	0.00	-1.83	0.08
2026-03-10	EVO	0.00	-1.83	0.08
2026-03-11	EVO	0.00	-1.83	0.10
2026-03-12	EVO	0.00	-1.83	0.10
2026-03-13	EVO	0.00	-1.83	0.10
2026-03-17	EVO	0.00	-1.86	0.10
2026-03-18	EVO	0.00	-1.86	0.10
2026-03-19	EVO	0.00	-1.86	0.10
2026-03-20	EVO	0.00	-1.86	0.10
2026-03-23	EVO	0.00	-2.11	0.10
2026-03-24	EVO	0.00	-2.11	0.10
2026-03-25	EVO	0.00	-2.11	0.12
2026-03-26	EVO	0.00	-2.11	0.12
2026-03-27	EVO	0.00	-2.11	0.12
2026-03-30	EVO	0.00	-2.13	0.12
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.07

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-2.13

Beta

1.93

Average Sales Estimate Current Quarter

239

Average Sales Estimate Next Quarter

215

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-91.3

Target Price

3.8

P/E

Forward P/E

PEG

P/S

1.01

P/B

0.89

P/Free Cash Flow

EPS

-0.5

Average EPS Est. Cur. Y

-0.66

EPS Next Y. (Est.)

-0.35

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-21.2

Relative Volume

1.22

Return on Equity vs Sector %

-47.3

Return on Equity vs Industry %

-27

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.13

EBIT Estimation

106.9

◆ EVO Healthcare

$2.36

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

12/20

Pullback

15/25

Volume

4/15

Valuation

12/20

TP/AR

1/10

Options

0/10

RSI

32.7

Range 1M

4.6%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

4/25

Growth

13/30

Estimates

0/20

Inst/Vol

2/15

Options

0/10

EPS Yr

59%

EPS NY

10%

52W%

1.9%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +61% upside

Quality

3/30

Valuation

14/30

Growth

8/25

Stability

5/10

LT Trend

4/5

Upside

+61%

Quality

Evotec SE

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 4788

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. It has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. The company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

EVO

Latest News

—

Caricamento notizie per EVO…

stock quote shares EVO – Evotec SE Stock Price stock today

news today EVO – Evotec SE stock forecast ,stock prediction 2023 2024 2025

marketwatch EVO – Evotec SE yahoo finance google finance

stock history EVO – Evotec SE invest stock market

stock prices EVO premarket after hours

ticker EVO fair value insiders trading

EOLS – Evolent Health Inc.

EOLS — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

15.29

Margin Of Safety %

Put/Call OI Ratio

0.4

EPS Next Q Diff

EPS Last/This Y

0.68

EPS This/Next Y

0.36

Price

3.95

Target Price

14.67

Analyst Recom

1.29

Performance Q

-42.9

Upside

-810.7%

Beta

0.99

Ticker: EOLS

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-02	EOLS	4.28	0.36	0.73	13316
2026-03-03	EOLS	4.12	0.37	1.75	13453
2026-03-04	EOLS	5.59	0.37	0.36	13625
2026-03-05	EOLS	5.67	0.39	0.34	14705
2026-03-06	EOLS	5.54	0.42	14.57	14683
2026-03-09	EOLS	5.36	0.42	2.09	14788
2026-03-10	EOLS	5.29	0.42	8.33	14763
2026-03-11	EOLS	5.39	0.42	999.99	14814
2026-03-12	EOLS	4.91	0.42	2.12	14811
2026-03-13	EOLS	4.91	0.42	1.96	14811
2026-03-17	EOLS	4.92	0.45	47.00	14964
2026-03-18	EOLS	4.84	0.46	0.43	15025
2026-03-19	EOLS	4.86	0.46	1.67	15040
2026-03-20	EOLS	4.64	0.46	0.02	15056
2026-03-23	EOLS	4.68	0.39	0.32	13618
2026-03-24	EOLS	4.44	0.39	0.95	13628
2026-03-25	EOLS	4.36	0.39	0.33	13634
2026-03-26	EOLS	4.18	0.39	1.36	13772
2026-03-27	EOLS	4.01	0.39	2.43	13798
2026-03-30	EOLS	3.94	0.40	0.75	13816
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	EOLS	4.28	163.8	13.7	-0.39
2026-03-03	EOLS	4.12	163.8	14.2	-0.39
2026-03-04	EOLS	5.59	163.8	7.5	-0.39
2026-03-05	EOLS	5.67	163.8	13.3	-0.39
2026-03-06	EOLS	5.53	163.8	14.0	-0.39
2026-03-09	EOLS	5.37	30.9	21.7	-0.12
2026-03-10	EOLS	5.29	30.9	15.2	-0.12
2026-03-11	EOLS	5.39	30.9	14.8	-0.12
2026-03-12	EOLS	4.92	30.9	16.1	-0.12
2026-03-13	EOLS	5.02	30.9	14.7	-0.12
2026-03-17	EOLS	4.91	30.9	15.4	-0.12
2026-03-18	EOLS	4.84	30.9	15.2	-0.12
2026-03-19	EOLS	4.87	30.9	14.9	-0.12
2026-03-20	EOLS	4.64	30.9	15.6	-0.12
2026-03-23	EOLS	4.69	30.9	14.9	-0.12
2026-03-24	EOLS	4.43	30.9	15.7	-0.12
2026-03-25	EOLS	4.36	30.9	15.2	-0.12
2026-03-26	EOLS	4.18	30.9	15.5	-0.12
2026-03-27	EOLS	4.01	30.9	15.5	-0.12
2026-03-30	EOLS	3.95	30.9	15.2	-0.12
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	EOLS	-0.07	-9.25	15.71
2026-03-03	EOLS	-0.08	-9.25	15.71
2026-03-04	EOLS	-0.08	-9.25	15.71
2026-03-05	EOLS	-0.08	-9.25	15.71
2026-03-06	EOLS	-0.08	-9.25	15.65
2026-03-09	EOLS	-0.08	-9.09	15.65
2026-03-10	EOLS	-0.08	-9.09	15.65
2026-03-11	EOLS	-0.08	-9.09	15.67
2026-03-12	EOLS	-0.08	-9.09	15.67
2026-03-13	EOLS	-0.08	-9.09	15.67
2026-03-17	EOLS	-0.08	-9.08	15.67
2026-03-18	EOLS	-0.08	-9.08	15.67
2026-03-19	EOLS	-1.04	-9.08	15.67
2026-03-20	EOLS	-1.04	-9.08	15.67
2026-03-23	EOLS	-1.14	-9.08	15.67
2026-03-24	EOLS	-1.14	-9.08	15.67
2026-03-25	EOLS	-1.14	-9.08	15.29
2026-03-26	EOLS	-1.14	-9.08	15.29
2026-03-27	EOLS	-1.14	-9.08	15.29
2026-03-30	EOLS	-1.14	-9.18	15.29
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.12

Avg. EPS Est. Next Quarter

-0.05

Insider Transactions

-1.14

Institutional Transactions

-9.18

Beta

0.99

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

77.8

Max Drawdown 5-Year %

-77.1

Target Price

14.67

P/E

Forward P/E

19.38

PEG

P/S

0.86

P/B

P/Free Cash Flow

EPS

-0.8

Average EPS Est. Cur. Y

-0.12

EPS Next Y. (Est.)

0.24

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-17.38

Relative Volume

0.62

Return on Equity vs Sector %

196.1

Return on Equity vs Industry %

216.4

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.05

EBIT Estimation

15.2

◆ EOLS Healthcare

$3.94

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

21/25

Volume

9/15

Valuation

15/20

TP/AR

2/10

Options

8/10

RSI

31.9

Range 1M

3.8%

Sup Dist

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

13/25

Growth

25/30

Estimates

1/20

Inst/Vol

0/15

Options

5/10

EPS Yr

63.6%

EPS NY

227.1%

52W%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +158.7% upside

Quality

7/30

Valuation

18/30

Growth

17/25

Stability

6/10

LT Trend

4/5

Upside

+158.7%

Quality

Evolus, Inc. Common Stock

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 334

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

EOLS

Latest News

—

Caricamento notizie per EOLS…

stock quote shares EOLS – Evolent Health Inc. Stock Price stock today

news today EOLS – Evolent Health Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch EOLS – Evolent Health Inc. yahoo finance google finance

stock history EOLS – Evolent Health Inc. invest stock market

stock prices EOLS premarket after hours

ticker EOLS fair value insiders trading

AYTU – Aytu BioPharma Inc.

AYTU — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

5.23

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.85

EPS Last/This Y

0.7

EPS This/Next Y

1.64

Price

2.61

Target Price

9.67

Analyst Recom

Performance Q

7.55

Upside

-5,210.3%

Beta

0.28

Ticker: AYTU

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-02	AYTU	2.64	N/A	N/A	0
2026-03-03	AYTU	2.67	N/A	N/A	0
2026-03-04	AYTU	2.645	N/A	N/A	0
2026-03-05	AYTU	2.55	N/A	N/A	0
2026-03-06	AYTU	2.54	N/A	N/A	0
2026-03-09	AYTU	2.64	N/A	N/A	0
2026-03-10	AYTU	2.6	N/A	N/A	0
2026-03-11	AYTU	2.62	N/A	N/A	0
2026-03-12	AYTU	2.68	N/A	N/A	0
2026-03-13	AYTU	2.64	N/A	N/A	0
2026-03-17	AYTU	2.6	N/A	N/A	0
2026-03-18	AYTU	2.63	N/A	N/A	0
2026-03-19	AYTU	2.6	N/A	N/A	0
2026-03-20	AYTU	2.64	N/A	N/A	0
2026-03-23	AYTU	2.62	N/A	N/A	0
2026-03-24	AYTU	2.66	N/A	N/A	0
2026-03-25	AYTU	2.71	N/A	N/A	0
2026-03-26	AYTU	2.67	N/A	N/A	0
2026-03-27	AYTU	2.57	N/A	N/A	0
2026-03-30	AYTU	2.64	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	AYTU	2.64	-	-	-1.59
2026-03-03	AYTU	2.69	-	-	-1.59
2026-03-04	AYTU	2.62	-	-	-1.59
2026-03-05	AYTU	2.59	-	-	-1.59
2026-03-06	AYTU	2.51	-	-	-1.59
2026-03-09	AYTU	2.62	-	-	-1.59
2026-03-10	AYTU	2.61	-	-	-1.59
2026-03-11	AYTU	2.61	-	-	-1.59
2026-03-12	AYTU	2.68	-	-	-1.59
2026-03-13	AYTU	2.58	-	-	-1.59
2026-03-17	AYTU	2.60	-	-	-1.59
2026-03-18	AYTU	2.64	-	-	-1.59
2026-03-19	AYTU	2.61	-	-	-1.59
2026-03-20	AYTU	2.62	-	-	-1.47
2026-03-23	AYTU	2.62	-	-	-1.47
2026-03-24	AYTU	2.65	-	-	-1.47
2026-03-25	AYTU	2.65	-	-	-1.47
2026-03-26	AYTU	2.65	-	-	-1.47
2026-03-27	AYTU	2.62	-	-	-1.47
2026-03-30	AYTU	2.61	-	-	-1.47
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	AYTU	0.00	10.63	4.67
2026-03-03	AYTU	0.00	10.63	4.67
2026-03-04	AYTU	0.00	10.63	4.67
2026-03-05	AYTU	0.00	10.63	4.67
2026-03-06	AYTU	0.00	10.63	4.67
2026-03-09	AYTU	0.00	10.63	4.67
2026-03-10	AYTU	0.00	10.63	4.67
2026-03-11	AYTU	0.00	10.63	4.85
2026-03-12	AYTU	0.00	10.63	4.85
2026-03-13	AYTU	0.00	10.63	4.85
2026-03-17	AYTU	0.00	10.63	4.85
2026-03-18	AYTU	0.00	10.63	4.85
2026-03-19	AYTU	0.00	10.63	4.85
2026-03-20	AYTU	0.00	10.63	4.85
2026-03-23	AYTU	0.00	10.63	4.85
2026-03-24	AYTU	0.00	10.63	4.85
2026-03-25	AYTU	0.00	10.63	5.23
2026-03-26	AYTU	0.00	10.63	5.23
2026-03-27	AYTU	0.00	10.63	5.23
2026-03-30	AYTU	0.00	10.63	5.23
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-1.05

Avg. EPS Est. Current Quarter

-0.61

Avg. EPS Est. Next Quarter

-0.2

Insider Transactions

Institutional Transactions

10.63

Beta

0.28

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

98.3

Max Drawdown 5-Year %

-99.4

Target Price

9.67

P/E

Forward P/E

PEG

P/S

0.45

P/B

1.99

P/Free Cash Flow

EPS

-3.84

Average EPS Est. Cur. Y

-1.47

EPS Next Y. (Est.)

0.17

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-39.02

Relative Volume

0.85

Return on Equity vs Sector %

-199.6

Return on Equity vs Industry %

-179.3

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.13

EBIT Estimation

◆ AYTU Healthcare

$2.63

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

0/20

Pullback

11/25

Volume

7/15

Valuation

9/20

TP/AR

2/10

Options

0/10

RSI

54.8

Range 1M

71.4%

Sup Dist

2.3%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

3/25

Growth

17/30

Estimates

0/20

Inst/Vol

7/15

Options

0/10

EPS Yr

45.1%

EPS NY

81.5%

52W%

79%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +166.6% upside

Quality

6/30

Valuation

18/30

Growth

13/25

Stability

3/10

LT Trend

1/5

Upside

+166.6%

Quality

Aytu BioPharma, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 82

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

AYTU

Latest News

—

Caricamento notizie per AYTU…

stock quote shares AYTU – Aytu BioPharma Inc. Stock Price stock today

news today AYTU – Aytu BioPharma Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch AYTU – Aytu BioPharma Inc. yahoo finance google finance

stock history AYTU – Aytu BioPharma Inc. invest stock market

stock prices AYTU premarket after hours

ticker AYTU fair value insiders trading

RGC – Regencell Bioscience Holdings Ltd

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: RGC

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

TXMD – TherapeuticsMD Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: TXMD

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y